Stockscreener 앱 받기
2.90
2.11%
0.06
시간 외 거래:
2.90
Polypid Ltd 주식(PYPD)의 최신 뉴스
PolyPid Completes Enrollment in Phase 3 Trial for Surgical Infection Prevention - TipRanks
PolyPid Announces Successful Completion of Enrollment in - GlobeNewswire
PolyPid Announces Successful Completion Of Enrollment In Phase 3 Shield II Trial Of D-Plex100 For The Prevention Of Abdominal Colorectal Surgical Site Infections - Marketscreener.com
Major Breakthrough: DSMB Backs Early Completion of Surgical Infection Prevention Trial - StockTitan
Critical Survey: Nyxoah (NASDAQ:NYXH) vs. PolyPid (NASDAQ:PYPD) - Defense World
PolyPid (NASDAQ:PYPD) Stock Price Up 0.7% – Should You Buy? - Defense World
PolyPid to Participate in the 37th Annual ROTH Conference - GlobeNewswire
PolyPid Fireside Chat at ROTH Conference: What New Surgical Innovations Will Management Reveal? - StockTitan
Polypid Ltd to Host Earnings Call - ACCESS Newswire
PolyPid Ltd. Earnings Call Highlights Promising Prospects - TipRanks
PolyPid Ltd. (NASDAQ:PYPD) Q4 2024 Earnings Call Transcript - Insider Monkey
PolyPid Ltd. Reports Positive Trial Progress and Financial Outlook - TipRanks
PolyPid targets SHIELD II trial completion with top-line results in Q2 2025 - MSN
PolyPid Updates: New Board Appointment and SHIELD II Trial Progress - TipRanks
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results - The Manila Times
PolyPid's Phase 3 Trial Nears Completion: Key Financial Updates Reveal Path to Critical Q2 2025 Results - StockTitan
PolyPid (PYPD) to Release Earnings on Wednesday - Defense World
Head-To-Head Contrast: PolyPid (NASDAQ:PYPD) versus OraSure Technologies (NASDAQ:OSUR) - Defense World
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Surgical Outcomes Pioneer PolyPid Takes Center Stage at Major Healthcare Conference - StockTitan
PolyPid Ltd. to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
PolyPid (NASDAQ:PYPD) Stock Rating Upgraded by RODMAN&RENSHAW - Defense World
PolyPid to Report Fourth Quarter and Full-Year 2024 - GlobeNewswire
Major Surgical Innovation Updates Expected: PolyPid Sets Critical Q4 Earnings Date - StockTitan
Rodman & Renshaw sets PolyPid stock at Buy with $13 target - MSN
PolyPid Regains Nasdaq Compliance with Private Placement Boost - TipRanks
Surgical Site Infections Pipeline 2024: Key Companies, MOA, - openPR
Critical Survey: InfuSystem (NYSE:INFU) vs. PolyPid (NASDAQ:PYPD) - Defense World
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress By Investing.com - Investing.com Australia
Earnings call transcript: PolyPid Q3 2024 focuses on trial progress - Investing.com India
PolyPid Ltd. announced that it expects to receive $14.470133 million in funding - Marketscreener.com
FY2024 Earnings Forecast for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Price Target Lowered to $11.00 at HC Wainwright - Defense World
PolyPid Advances Phase 3 Trial and Secures Financing - TipRanks
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright - Investing.com Australia
PolyPid stock poised for 2026 launch despite adjusted target from H.C. Wainwright By Investing.com - Investing.com South Africa
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million - The Manila Times
PolyPid's Surgical Infection Drug Trial Advances with $14.5M Funding Boost; Phase 3 Results Due Q2 2025 - StockTitan
FY2024 Earnings Estimate for PolyPid Issued By HC Wainwright - Defense World
PolyPid (NASDAQ:PYPD) Given “Buy” Rating at HC Wainwright - Defense World
Critical Survey: PAVmed (NASDAQ:PAVM) and PolyPid (NASDAQ:PYPD) - Defense World
PolyPid announces collaboration with ImmunoGenesis in solid tumors - The Cancer Letter
3.70%
자본화:
|
볼륨(24시간):